<DOC>
	<DOCNO>NCT00438880</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , agatolimod sodium , may stimulate immune system different way stop cancer cell grow . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Radiolabeled monoclonal antibody , yttrium Y 90 ibritumomab tiuxetan , find cancer cell carry cancer-killing substance without harm normal cell . Giving agatolimod sodium together rituximab yttrium Y 90 ibritumomab tiuxetan may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose agatolimod sodium give together rituximab yttrium Y 90 ibritumomab tiuxetan see well work treat patient recurrent refractory non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Agatolimod Sodium , Rituximab , Yttrium Y 90 Ibritumomab Tiuxetan Treating Patients With Recurrent Refractory Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose CpG 7909 deliver four dos ( day 6 , 13 , 20 , 27 ) patient relapse CD20+ non-Hodgkin 's lymphoma . ( Phase I ) II . To assess toxicity CpG 7909 combine rituximab Y-90 Zevalin patient lymphoma . ( Phase I ) III . To assess overall response rate ( CR + PR ) regimen relapse diffuse large B cell lymphoma . ( Phase II ) IV . To assess toxicity treatment regimen patient relapse diffuse large B cell lymphoma . ( Phase II ) V. To assess time progression duration response patient relapse diffuse large B cell lymphoma . ( Phase II ) SECONDARY OBJECTIVES : I . To report response rate ( complete remission + complete remission unconfirmed + partial remission ) patient population CpG 7909 , rituximab , Y-90 Zevalin . ( Phase I ) II . To compare biodistribution In-111 Zevalin radioimmunoconjugate scan CpG 7909 . ( Phase I ) III . To determine HAMA/HACA rate patient treat regimen . ( Phase I ) IV . To determine CpG 7909 give context rituximab Y-90 Zevalin stimulate immune effector cell blood tumor tissue . ( Phase I ) OUTLINE : This dose escalation study agatolimod sodium follow phase II study . PHASE I ( patient relapse , refractory , residual CD20+ non-Hodgkin lymphoma [ close accrual 10/29/07 ] ) : Patients receive rituximab IV day 1 , 8 15 , agatolimod sodium IV 2 hour day 6 , 13 , 20 , 27 , yttrium Y 90 ibritumomab tiuxetan* IV 10 minute day 15 absence disease progression unacceptable toxicity . *NOTE : Patients receive indium In 111 ibritumomab tiuxetan IV 10 minute day 1 8 . Patients undergo whole-body gamma camera imaging , single-photon emission compute tomography/CT scan , blood sample dose indium In 111 ibritumomab tiuxetan determine biodistribution . If biodistribution acceptable , patient receive yttrium Y 90 ibritumomab tiuxetan . PHASE II ( patient relapse , refractory , residual diffuse large B-cell lymphoma ) : Patients receive agatolimod sodium MTD determine phase I . Patients receive rituximab yttrium Y 90 ibritumomab tiuxetan phase I . *NOTE : Patients receive indium In 111 ibritumomab tiuxetan IV 10 minute day 8 . Patients undergo whole-body gamma camera image blood sample dose indium In 111 ibritumomab tiuxetan determine biodistribution . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>The following histologic type REAL classification International Working Formulation ( IWF ) applicable ( NOTE : Closed accrual 10/29/07 ) : Small lymphocytic lymphoma ; Lymphoplasmacytoid lymphoma ; Follicular center lymphoma , follicular grade 1 , 2 , 3 ; Extranodal marginal zone B cell lymphoma MALT type ; Nodal marginal zone B cell lymphoma The following histologic type REAL classification International Working Formulation ( IWF ) applicable : Diffuse large cell ; Transformed lymphoma Less 25 % bone marrow involvement cellular marrow lymphoma determine bilateral bone marrow aspirate biopsy ( percent involvement estimate hematopathologist use biopsy material ) There limit number prior therapy ( patient previously receive rituximab eligible ) Bidimensionally measurable disease : The patient must &gt; = 1 lesion single diameter &gt; = 2 cm Absolute neutrophil count &gt; = 1500/mm^3 Platelet count &gt; = 150,000 Total lymphocyte count &lt; 5000/mm^3 patient small lymphocytic lymphoma HGB &gt; = 8 Biopsyproven relapse , refractory , residual CD20+ nonHodgkin 's lymphoma ; previous biopsy = &lt; 6 month prior treatment protocol acceptable long intervene therapy ; patient receive therapy NHL time last biopsy protocol , rebiopsy necessary ECOG performance status ( PS ) 0 , 1 , 2 Expected survival &gt; = 3 month Willingness provide biologic specimen require protocol Total bilirubin = &lt; 2 x ULN mg/dL ( abnormal , direct bilirubin = &lt; 1.5 x ULN ) Prior myeloablative therapy autologous allogeneic bone marrow transplantation peripheral blood stem cell support Prior radioimmunotherapy include Y90 Zevalin 131Iodine antiB1 antibody Lym1 Presence CNS lymphoma Serious nonmalignant disease active infection condition opinion investigator would compromise protocol objective Major surgery diagnostic surgery = &lt; 4 week prior registration Another active primary malignancy Known HAMA/HACA ( Human antimouse antichimeric antibody ) Myelodysplastic syndrome marrow chromosomal change suggest myelodysplasia Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , abstinence , etc . ) Failed stem cell collection Marrow cellularity = &lt; 15 % ( determine bone marrow sample ) Known lymphoma relate HIV AIDS ( patient exclude unknown effect prolong Bcell depletion patient 's immune system ) GCSF GMCSF therapy = &lt; 1 week prior study registration ( pegylated filgrastim = &lt; 3 week ) Myelosuppressive chemotherapy = &lt; 3 week prior study registration ( = &lt; 6 week rituximab , nitrosourea , Mitomycin C ) Skin rash ( StevensJohnson 's syndrome toxic epidermal necrolysis ) prior rituximab therapy enter study risk reoccurrence skin toxicity Abnormal renal function ( serum creatinine &gt; 2 mg/dL ) Preexistent clinical autoimmune antibody mediate disease , include systemic lupus erythematosus , rheumatoid arthritis , multiple sclerosis , Sjogren 's syndrome , autoimmune thrombocytopenia ( patient clinical symptom disease , merely previously detect antibody eligible ) Received prior external beam radiation therapy &gt; 25 % active bone marrow Corticosteroid therapy time patient enters protocol ; patient use prednisone equivalent adrenal failure use &lt; 20mg prednisone/day benign cause accept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>